论文部分内容阅读
[目的]探讨奥曲肽联合固本消胀汤治疗恶性肠梗阻的临床疗效。[方法]将33例恶性肠梗阻患者随机分为2组:治疗组16例,对照组17例。治疗组在常规治疗(即禁食,胃肠减压,抗感染,维持水电解质平衡,营养支持,止痛等)基础上,予固本消胀汤煎剂鼻饲,100ml/次,2次/d,鼻饲后夹闭胃管2h,同时予奥曲肽持续静脉泵入,25μg/h,治疗7d。对照组在常规治疗基础上予奥曲肽持续静脉泵入,25μg/h,治疗7d。[结果]治疗组完全缓解5例,部分缓解10例,无效1例,有效率93.8%。对照组完全缓解2例,部分缓解7例,无效8例,有效率52.9%。与治疗前比较,患者临床症状、腹部平片、胃肠减压引流量、KPS评分、1年生存率治疗后明显改善,差异有统计学意义(P<0.05)。[结论]奥曲肽联合固本消胀汤治疗恶性肠梗阻的临床有效率高,显示中西医联合治疗恶性肠梗阻的优势,值得临床推广。
[Objective] To investigate the clinical efficacy of octreotide combined with Gubenxiaozhang decoction in the treatment of malignant intestinal obstruction. [Methods] Thirty-three patients with malignant intestinal obstruction were randomly divided into two groups: treatment group (16 cases) and control group (17 cases). On the basis of routine treatment (ie fasting, decompression of gastrointestinal tract, anti-infective, maintaining water and electrolyte balance, nutritional support, analgesia and so on), the treatment group was given Gubengxiao decoction nasal feeding 100ml / time, twice daily , After the nasogastric tube closed 2h, while octreotide sustained intravenous injection, 25μg / h, treatment 7d. The control group on the basis of conventional treatment of octreotide continuous intravenous injection, 25μg / h, treatment of 7d. [Results] In the treatment group, 5 cases were completely relieved, 10 cases partially relieved, 1 ineffective, and the effective rate was 93.8%. In the control group, 2 cases were completely relieved, 7 cases partially relieved, 8 ineffective, and the effective rate was 52.9%. Compared with before treatment, clinical symptoms, abdominal plain film, gastrointestinal decompression and drainage, KPS score, 1-year survival rate after treatment significantly improved, the difference was statistically significant (P <0.05). [Conclusion] The clinical effective rate of octreotide combined with Gubenxiaozhang Decoction in treating malignant intestinal obstruction is high, which shows the advantage of combining traditional Chinese and western medicine in the treatment of malignant intestinal obstruction and is worthy of clinical promotion.